Search PubMedSearch

PubMed · 42644315

Evaluation of methacrylic resin-modified calcium silicate cements for pulpal healing using an experimental pulpitis model.

Abstract

Recently, vital pulp treatment (VPT), including direct pulp capping, which preserves pulp vitality and extends the functional lifespan of teeth, has garnered significant attention. The purpose of this study was to evaluate the performance of calcium silicate cement, the gold standard for VPT, alongside hydraulic calcium silicate cement (Pro-MTA), a material with extensive evidence of effectiveness, Bis-GMA resin-modified calcium silicate cement (TH), and a newly developed material, methacrylate resin-modified calcium silicate cement (RM-MTA), in a model of pulpitis induced by caries progression. Additionally, the calcium ion (Ca2+) release capacity of these materials and their comprehensive effects on pulpal wound healing were assessed using RNA sequencing (RNA-seq). In both sound pulp models and caries-induced pulpitis models, RM-MTA and Pro-MTA exhibited similar performances. Unlike TH, they induced significant tertiary dentin formation within the dental pulp beneath the material, without any residual inflammatory cells. Inflammation was specifically assessed with a focus on M1/M2 macrophages. While the timing of Ca2+ ion release differed among the materials, the total amount released was comparable, although the release of calcium ions (Ca2+) from TH was significantly lower compared to that observed for the above materials. Moreover, comprehensive genetic analysis revealed that the expression of cell proliferation-related genes was selectively reduced in TH, suggesting that differences in resin composition may account for these variations in behavior. These findings suggest that RM-MTA induces tertiary dentin and demonstrates biocompatibility comparable to that of Pro-MTA. This makes it suitable for the treatment of both sound and mildly inflamed pulp tissues. Additionally, its resin properties are expected to enhance both mechanical performance and clinical handling.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sayako Matsumoto, Motoki Okamoto, Huang Hailing, Kiichi Moriyama, Koki Nakatani, Masakatsu Watanabe, Jiro Miura, Yujiro Hirose, Shigetada Kawabata, Daisuke Okuzaki, Yusuke Takahashi, Mikako Hayashi. 2026-08-26. Evaluation of methacrylic resin-modified calcium silicate cements for pulpal healing using an experimental pulpitis model.. https://doi.org/10.1039/d5tb00570a

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article